IND application for ISTA

Article

ISTA Pharmaceuticals has submitted an Investigational New Drug (IND) application to the FDA for its eye drop formulation of bepotastine for the treatment of allergic conjunctivitis.

ISTA Pharmaceuticals has submitted an Investigational New Drug (IND) application to the FDA for its eye drop formulation of bepotastine for the treatment of allergic conjunctivitis.

Bepotastine has three primary mechanisms of action. It is a non-sedating, selective antagonist of the histamine 1 (H1) receptor; it has a stabilizing effect on mast cells and it suppresses the migration of eosinophils into inflamed tissues. ISTA plan to initiate Phase II/III clinical trials in the US during the first quarter of 2007.

An oral formulation of bepotastine has been approved in Japan since July 2000 for the treatment of allergic rhinitis.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.